| Document |
Document Title |
|
WO/2023/276966A1 |
The present invention provides: a pharmaceutical composition with which cancer cells present at various locations in the body can be killed locally and with high efficiency; and a method therefor. According to the present invention, a fu...
|
|
WO/2023/275715A1 |
The present invention provides compounds of Formula X-1, X-2, X-3, or X-4, or metabolites of Compound 1 or metabolites of a compound of Formula 3-A or 3-B, including compositions and salts thereof, which are useful in the prevention and/...
|
|
WO/2023/277638A1 |
The present invention relates to a mixture of three including lactobacillus fermentum strains and a lactobacillus plantarum strain, and the use thereof. A composition according to one aspect comprising a mixture of lactobacillus fermentu...
|
|
WO/2023/276768A1 |
Provided are: a novel marker useful for measuring hypoxia or predicting the exacerbation of pathoses related to hypoxia; a hypoxia measurement method and a pathosis exacerbation prediction method which use said marker as an indicator; a ...
|
|
WO/2023/276496A1 |
[Problem] To provide a composition having an enhanced antioxidant activity. [Solution] This composition contains component (1) and component (2). Component (1) is at least one selected from the group consisting of bisdemethoxycurcumin, g...
|
|
WO/2023/278364A1 |
A method for inducing synaptogenesis in a subject having a neurodegenerative disease, the method comprising administering an angiotensin or analogue thereof in a therapeutically effective amount to induce synaptogenesis in said subject. ...
|
|
WO/2023/277636A1 |
The present invention relates to an anti-aging composition adapted to administer a Lactobacillus sp. strain and a medicinal herb material in combination. An anti-aging composition adapted to administer a Lactobacillus sp. strain and a me...
|
|
WO/2023/277584A1 |
A composition for removing senescent cells according to the present invention comprises a selenium compound or a pharmaceutically acceptable salt thereof as an active ingredient, thereby inducing apoptosis of senescent cells to remove se...
|
|
WO/2023/277376A1 |
The present invention relates to a polypeptide, synthesized by linking 9 to 10 amino acids, for prevention or treatment of idiopathic pulmonary fibrosis, wherein the polypeptide comprises the amino acid sequence consisting of arginine (R...
|
|
WO/2023/276861A1 |
The present invention improves the sperm finding of mammalian animals, and in particular, male infertility patients. This composition for oral ingestion, which contains ergothioneine as an active component, is administered orally to a ...
|
|
WO/2023/275649A1 |
Disclosed herein are methods of increasing sensitivity of a cancer cell to alternating electric fields comprising exposing the cancer cell to an alternating electric field for a period of time, the alternating electric field having a fre...
|
|
WO/2023/275790A1 |
The present disclosure provides an enteral or urinary pharmaceutical formulation comprising (A) a compound of formula I, (I), wherein R1 is a C1-C3 alkyl; X is -C(R2)(R3)-C(R4)(R5)- or -C≡C-, wherein R2, R3, R4, and R5 are each indepen...
|
|
WO/2023/275622A2 |
The invention generally relates to methods and systems for controlling electrolyte excretion, e.g., sodium, potassium, chloride and bicarbonate, which is useful to remove body fluid during sweating.
|
|
WO/2023/273882A1 |
Disclosed is an efficient and non-genetically modified iPSC-induced, industrialized single clone selection platform, and a use. The platform can efficiently perform reprogramming, and only requires the use of a minimal number of reprogra...
|
|
WO/2023/275249A1 |
The present invention relates to anethole trithione (ATT) for use for preventing, treating, and/or lessening the severity or progression of, a vasculitis in a subject in need thereof, in particular of Kawasaki and Kawasaki-like disease.
|
|
WO/2023/276942A1 |
Disclosed is a pharmaceutical agent that inhibits expression of VEGFA in fibroblasts. This pharmaceutical agent can inhibit increase in expression of VEGFA in fibroblasts caused by infrared rays, heat, etc.
|
|
WO/2023/276828A1 |
The present invention addresses the problem of providing: a pharmaceutical composition for preventing and/or treating acute kidney injury; and an autophagy activator. The present invention relates to: a pharmaceutical composition for pre...
|
|
WO/2023/275132A1 |
The present invention relates to the field of medicine, in particular to internal and aesthetic regenerative medicine. More specifically, the present invention relates to a composition suitable for use as a transport medium for adipose t...
|
|
WO/2023/277075A1 |
The present invention addresses the problem of providing a topical skin agent containing a heparinoid and another active ingredient, wherein the storage stability of the heparinoid is improved. According to the present invention, there i...
|
|
WO/2023/277116A1 |
[Problem] To provide a therapeutic or prophylactic agent for various diseases associated with an opioid κ receptor, including pain, the therapeutic or prophylactic agent having opioid κ receptor agonist activity, while being reduced in...
|
|
WO/2023/276866A1 |
The present invention pertains to a therapeutic composition for Barrett's esophagus and addresses the problem of providing a therapeutic composition for restoring Barrett's esophagus to normal esophagus and a method for treating Barrett'...
|
|
WO/2023/277168A1 |
The present invention relates to a polynucleotide including a translation region from a start codon to a stop codon, a 5' untranslated region, and a poly-A tail, 65% or more of the nucleotides that constitute the poly-A tail being sugar-...
|
|
WO/2022/270200A1 |
[Problem] The purpose of the present invention is to provide a pharmaceutical formulation with which it is possible to inhibit separation in an aqueous topical composition containing at least 0.005 parts by weight of a nicotinic acid est...
|
|
WO/2022/270071A1 |
The present invention provides: an agent for preventing liver fibrosis, which comprises at least one nucleic acid selected from the group consisting of a nucleic acid that comprises a nucleotide sequence comprising a seed sequence for mi...
|
|
WO/2022/270487A1 |
The present invention addresses the problem of providing a compound having an ETA receptor antagonistic activity and others. The problem can be solved by a compound represented by formula (1) [wherein variables are as defined in the desc...
|
|
WO/2022/267673A1 |
The present invention relates to the technical field of biomedicines, and in particular to a sulfoximide substituted indazole compound, or an isomer and pharmaceutically acceptable salt thereof. The structure of the compound is shown as ...
|
|
WO/2022/269323A1 |
The present invention relates to daprodustat or a pharmaceutically acceptable salt thereof for use in reducing fatigue in non-dialysis subjects with anemia associated with chronic kidney disease. In particular embodiments, the invention ...
|
|
WO/2022/270523A1 |
This medicament characterized by containing an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein together or separately in combination with a pyrimidine drug, a platinum formulation, and an angioge...
|
|
WO/2022/269049A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, A, L1, L2, Y and Z are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formu...
|
|
WO/2022/268648A1 |
The present invention relates to compounds of formula I wherein Q is as pesticides for combating and controlling insects, acarines, nematodes or molluscs. An exemplary compound is e.g. 2-[3-[l[[6-chloro-8-(trifluoromethyl) quinazolin-4-y...
|
|
WO/2022/270524A1 |
This medicament characterized by containing an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein together or separately in combination with a topoisomerase I inhibitor is useful as a medicament for...
|
|
WO/2022/269539A1 |
The present disclosure concerns a probiotic composition comprising an effective amount of a probiotic product and an acceptable carrier. The probiotic composition can be used in favoring wellness and facilitating self-control in a subjec...
|
|
WO/2022/268825A1 |
The disclosure relates to oral formulations for gastric delivery of a pharmaceutically acceptable salt of a phenyl pyrrole aminoguanidine compound.
|
|
WO/2022/270612A1 |
The present disclosure provides an anti-CTLA-4 antibody and methods for producing and using same. The present disclosure also provides: a nucleic acid encoding said anti-CTLA-4 antibody; and host cells including said nucleic acid. The pr...
|
|
WO/2022/264014A1 |
Methods of using anamorelin to treat fatigue and increasing physical activity in defined cancerous patient populations.
|
|
WO/2022/265021A1 |
The present invention provides: a composition that contains atelocollagen and dermal sheath cup (DSC) cells; a kit for regrowing hair that includes a first agent containing atelocollagen and a second agent containing dermal sheath cup (D...
|
|
WO/2022/266039A1 |
The present disclosure relates to methods of determining and administering a treatment course of action. In particular, the present disclosure relates to compositions and methods for monitoring and treating stroke (e.g., with anti-inflam...
|
|
WO/2022/265092A1 |
The present invention addresses the problem of providing a treatment method that is more practical than currently reported methods in cancer treatment using sodium iodide symporter (NIS)-MSCs, and a composition for cancer treatment that ...
|
|
WO/2022/266440A1 |
Methods of treating sleep apnea and snoring comprising administering a norepinephrine reuptake inhibitor, optionally in the absence of an antimuscarinic agent, and optionally as a monotherapy, are described herein. Pharmaceutical composi...
|
|
WO/2022/265124A1 |
The present invention relates to the pharmaceutical use of a cord blood immunosuppressive cell and, more specifically, the present invention provides the use of a human-derived cord blood immunosuppressive cell, which is selected in acco...
|
|
WO/2022/265984A1 |
The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an NEP inhibitor or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for ...
|
|
WO/2022/264456A1 |
This substance, which specifically binds to the PEX domain (hemopexin domain) of MT1-MMP (MMP-14) and inhibits a MT1-MMP-mediated survival signal to active hepatic stellate cells (aHSCs), can reduce or kill the active hepatic stellate ce...
|
|
WO/2022/264966A1 |
The purpose of the present invention is to provide medical therapy for treating and/or preventing Rett syndrome (RTT), autism spectrum disorders, or schizophrenia, for which radical treatments have not yet been discovered. The present ...
|
|
WO/2022/263558A1 |
The present invention relates to the use of an improved curcuminoids composition for improving and/or maintaining functional performance and/or relieving, treating, decreasing and/or preventing muscle soreness in a subject during and/or ...
|
|
WO/2022/260064A1 |
The present invention provides: a pharmaceutical composition having excellent elution properties and uniform content, provided by mixing a p-toluenesulfonate of 7-[[2,3-difluoro-4-[2-[2-methoxyethyl(methyl)amino]ethoxy]ph
enyl]methyl]-10...
|
|
WO/2022/259993A1 |
The purpose of the present invention is to provide a novel PPARα transcription activator. The present invention relates to a compound given by formula (I) or a salt thereof [The symbols in the formula are as described in the Descripti...
|
|
WO/2022/261263A1 |
The disclosure provides, in part, a method of treating a neuropsychiatric disorder in a patient in need thereof, comprising administering to the patient an effective amount of an orexin receptor antagonist and further comprising administ...
|
|
WO/2022/259129A1 |
The present invention relates in particular to the use of sterol derivatives as Dectin-1 receptor ligands in the prevention and treatment of diseases related to said receptor. The invention also refers to compositions and uses of such st...
|
|
WO/2022/259211A1 |
An ophthalmic composition comprising: an adenosine receptor antagonist (e.g., caffeine or a related compound) or a combination of an adenosine receptor antagonist (e.g., caffeine or a related compound) and one or more parasympathomimetic...
|
|
WO/2022/258722A1 |
The present invention relates to a composition comprising the combination of (i) an extract obtained from plant material selected from the family Elaeagnaceae, and/or (ii) one or more flavonoid compound(s); in combination with (iii) an e...
|
